Immunofluorescence Assay Market Size was valued at USD 1.78 Billion in 2023. The Global Immunofluorescence Assay industry is projected to grow from USD 1.89 Billion in 2024 to USD 3.24 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.89% during the forecast period (2024 - 2032). The increase in biological studies in research and development for detection of biomolecules like proteins, glycans, and small biological and non-biological molecules of various diseases drives the market growth. Immunofluorescence Assays are used for rapid and sensitive diagnostics of various chronic diseases like cancer, autoimmune diseases, infectious diseases like HIV, neurological diseases such as Alzheimer's and Parkinson's disease and chronic diseases like cancer. Immunofluorescence assay is a primary detection test used for patients suspected with autoimmune disease.
According to National Institutes of Health (2012), autoimmune diseases are most prevalent among other diseases, and 23.5 million people in America suffer from autoimmune diseases, whereas 9 million people have cancer. Furthermore, according to Alzheimer's Association in 2018, 5.7 million Americans are affected by Alzheimer’s disease. Thus, such high incidence of autoimmune and neurological diseases and increasing government funding enhances the growth in this market. Also, growing demand for rapid and precise measurement of biomolecules, increased use of Immunofluorescence Assay for diagnostic and research purposes, increased R&D activities and advanced technology are the key factors for the market to grow.
However, factors such as expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.
In Jan 2023, Agilent and Akoya came together to create chromogenic and immunofluorescent multiplex assays that utilize spatial analysis for biopharmaceutical firms involved in the development of precise cancer therapies. These assay solutions enable researchers as well as healthcare providers to meet patient selection criteria for new drugs and rapidly translate their discoveries into clinical trials.
In June 2023, under Revvity, EUROIMMUN launched UNIQO 160, which is a ground-breaking automated system for indirect immunofluorescence testing (IIFT) used in autoimmune disease diagnostics. This advanced test helps improve the overall efficiency of the entire IIFT process, including sample preparation, incubation, slide washing, mounting, image acquisition and analysis.
In Dec 2023, First Light Diagnostics obtained FDA approval for its SensiTox B. anthracis Toxin Test, which is an immunofluorescence assay for early biomarkers of inhalational anthrax. The MultiPath Analyzer-compatible 20-minute test enables rapid and early diagnosis of anthrax infection. Federal funds from the U.S. Department of Health and Human Services supported this test’s development and that of the MultiPath Analyzer. Also cleared for sale in the United States by First Light are its SensiTox C.difficile Toxin Tests.
In September 2022, Vizgen released the MERSCOPE Protein Co-detection Kit to allow subcellular spatial multi-omics measurement with simultaneous detection of RNA and proteins during normal MERFISH experiments. The MERSCOPE Protein Stain Reagent Kit contains oligo-conjugated antibodies that enhance primary antibodies targeted at protein detection while ensuring quality protein staining equivalent to protein immunofluorescence staining was obtained. Therefore, it is expected that the factors mentioned above will contribute towards increasing market growth.
The global immunofluorescence assay market is segmented on the basis of technique, product type, application and end user. The immunofluorescence assay market, by technique, is sub-segmented into primary (direct) immunofluorescence assays, secondary (indirect) immunofluorescence assays, and microimmunofluorescence. Secondary (indirect) immunofluorescence assays category includes salt split technique, antigenic mapping method, and double staining method.
On the basis of product type, the market is categorized into antibodies, kits and reagents, instruments, labeling dyes and species type. Instruments are further sub-segmented into microscopes and imaging analysis systems. The application segment includes clinical research, clinical diagnostics, research & development. Clinical diagnostics segment is categorized into infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, neurological diseases. On the basis of end-user, the market is segmented into biotechnology companies, hospitals & research institutes, contract research organizations and diagnostic centers.
On the basis of region, the global Immunofluorescence Assay market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
The Immunofluorescence Assay market is dominated by North America owing to the high prevalence of chronic diseases and high R&D investments within this region stimulate market growth. According to the U.S. Investments in Medical and Health Research and Development in 2016, the United States invested total $171.8 billion in medical and health R&D and the investment increased by 20.6% from 2013 to 2016. Also, the rising adoption of technologically advanced systems for early diagnosis of diseases drives the market growth in this region.
It is estimated that Europe stood second in the global Immunofluorescence Assay market. Rising prevalence of chronic diseases such as cancer is driving the growth of this market in Europe. According to the Eurostat in 2014, 272 thousand people deaths were due to lung cancer. Thus, increasing prevalence of cancer in Europe drives the market growth. Furthermore, rapidly growing biotechnology sector in Europe is expected to boost the market in this region.
Asia Pacific was projected to be the fastest growing region for the global Immunofluorescence Assay market. Key factors such as growing patient pool, high incidence of chronic diseases, developing healthcare infrastructure and increasing research & development activities in biotechnology sector influences the market in this region. Also, the presence of major market players China, India, and Japan drive the market growth.
The Middle East and Africa holds the least share in the global Immunofluorescence Assay market due to the presence of stringent government policies and poor economies. However, growing awareness among the population and high investments by private market players in this region can boost the market growth.
Research Methodology
Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global Immunofluorescence Assay market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | Â 3.24 Billion |
| CAGR | Â 7.89% |
| Base Year | Â Â 2022 |
| Forecast Period | Â Â 2024-2032 |
| Historical Data | Â Â 2021 |
| Forecast Units | Â Â Value (USD Billion) |
| Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, application and End User |
| Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Abcam plc, Thermo Fisher Scientific, BioLegend, Inc., Enzo Life Sciences, Inc., Sino Biological Inc., BioTek Instruments, Inc., Bio-Rad Laboratories, Inc., Zyagen, Cell Signaling Technology, Inc., PerkinElmer Inc., Becton Dickinson and Company, Merck, Agilent Technologies, TCS Biosciences Ltd,, Maxvision Biosciences Inc. |
Frequently Asked Questions (FAQ) :
The global immunofluorescence assay market can grow with 7.89% CAGR during the forecast period of 2024-2032
Growing demand for autoimmune disease detection can inspire growth for the immunofluorescence assay market.
Factors like chances of cross contaminations, expensive diagnostic kits, lack of skilled labor, and weak detection signals can prevent the immunofluorescence assay market from growth.
The immunofluorescence assay market applications mostly take place in segments like clinical diagnostics, clinical research, research & development.
The North American immunofluorescence assay market would have the edge in the global competition.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
